VBL Therapeutics: Jumps on plan to hasten ovarian cancer drug development

Notable Labs

03/06/2021 13:07

** Shares of the drug developer  VBLT.O  jump 4.2%
premarket, set to open at an over three-month high of $2.49 
    ** Co says added a second main goal, following discussion
with FDA, in its late stage trial of a biologic, VB111, in
patients with platinum resistant ovarian cancer  urn:newsml:reuters.com:*:nFWN2NL048
    ** Says FDA agreed that meeting either main goals sufficient
to support a marketing approval application for VB111; could
accelerate approval submission by about one year
    ** Stock up 26% YTD, as of last close

 (Reporting by Susan Mathew in Bengaluru)
 ((susan.mathew@thomsonreuters.com; +91-80-6287-2704;))